Medical Advocates
HAART/ART
 
Main Page

New/Noteworthy   
 Guidelines     
 Children
 Adolescents
 Pregnant Women
 Women
 General Reports 
 Efficacy
 HAART Errors
Drug Interactions       
Adverse Events
 Viral Dynamics
Adherence
Resistance
 Body Mass
 Quality-of-Life
 Dosing
 Therapeutic Strategies
 Economics
 HIV Transmission
 HIV/HCV Coinfection
 Disease Progression
 Drug Index
Drug Classes
 HAART/ART Failure
HIV Main Page Main New/Newsworthy    Home Page    
This web page is best viewed by using INTERNET EXPLORER
Last Update:  July 24, 2008  
  Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
New and Noteworthy
     
July 2008
 
June 2008
 
General/Miscellaneous Reports
 

     Journal Papers, Abstracts, and Commentaries

 
Poor Initial CD4+ Recovery With Antiretroviral Therapy Prolongs Immune Depletion and Increases Risk
for AIDS and Non-AIDS
Diseases.
Baker JV, Peng G, Rapkin J, et al
J Acquir Immune Defic Syndr. 2008 Jul 12.
 Abstract
 
Therapy analysis and evidenced-based treatment guidelines (including review of antiviral medications).
Smith J.
J Manag Care Pharm. 2008 Jun;14(5):7-11.
 Abstract
 
Managing antiretroviral therapy: changing regimens, resistance testing, and the risks from
structured treatment interruptions.
Eron JJ.
J Infect Dis. 2008 May 15;197
Abstract
 
Effects of antiretroviral therapy on cognitive impairment.
Liner Ii KJ, Hall CD, Robertson KR.
 Curr HIV/AIDS Rep. 2008 May;5(2):64-71
 Abstract
 
Potential for New Antiretrovirals to Address Unmet Needs in the Management of HIV-1 Infection.
Moyle G, Gatell J, Perno CF, et al
AIDS Patient Care STDS. 2008 May 14.
Abstract
 
Effects of HIV antiretrovirals on the pharmacokinetics of hormonal contraceptives.
 El-Ibiary SY, Cocohoba JM. 
Eur J Contracept Reprod Health Care. 2008 Jun;13(2):123-32.
 Abstract
 
Does Antiretroviral Therapy Prevent HIV Transmission to Sexual Partners?
Lalani T, Hicks C.z
Curr Infect Dis Rep. 2008 May;10(2):140-5.
 Abstract
 
Immunological rebound after initiation of highly active antiretroviral therapy in
treatment-naive patients.
Blackard JT, Welles SL, Ackerman A, et al
A  IDS Res Hum Retroviruses. 2008 Mar;24(3):499-504.
Abstract
 
A WEEK IN REVIEW FEATURED REPORT
 FULL TEXT PDF ARTICLE
 Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral
therapy.
Palmer S, Maldarelli F, Wiegand A, et al 
Proc Natl Acad Sci U S A. 2008 Mar 10
Paper
 
Antiretroviral therapy: Principles for treating HIV infection.
Launay O.
Presse Med. 2008 Feb 29
 Abstract
 
New approaches to the treatment of the HIV-infected patient
Chandrika K, Dellot P, Frippiat F, et al  
Rev Med Liege. 2007;62 Spec No:47-50.
 Abstract
 
Part XV. antiretroviral therapy for human immunodeficiency virus infection.
Stephens JR, Rathbun RC, Lockhart SM, et al
J Okla State Med Assoc. 2007 Nov;100(11):417-24
 Abstract
 
The safety of antiretroviral drugs.
 Tymchuk CN, Currier JS. 
Expert Opin Drug Saf. 2008 Jan;7(1):1-4.
 Abstract
 
Unmeasured confounding caused slightly better response to HAART within than
outside a randomized controlled trial.
 Eg Hansen AB, Gerstoft J, Kirk O, et al 
J Clin Epidemiol. 2008 Jan;61(1):87-94.
 Abstract
 
Changes in Outcome of Persons Initiating Highly Active Antiretroviral Therapy at a CD4
Count Less Than 50 Cells/mm3.
 Porter K, Walker S, Hill T, Anderson J, et al
 J Acquir Immune Defic Syndr. 2007 Oct 25;
 Abstract
 
The Influence of Psychosocial Characteristics and Race/Ethnicity on the Use, Duration,
and Success of Antiretroviral Therapy.
 Pence BW, Ostermann J, Kumar V, et al
 J Acquir Immune Defic Syndr. 2007 Oct 25;
Abstract
 
Late diagnosis of HIV infection: epidemiological features, consequences and strategies to
encourage earlier testing
 Girardi E, Sabin CA, Monforte AD, et al
J Acquir Immune Defic Syndr. 2007 Sep;46 Suppl 1:S3-8.
Abstract
 
Patient preferences among third agent HIV medications: a US and German perspective.
 Beusterien KM, Dziekan K, Schrader S, et al 
AIDS Care. 2007 Sep;19(8):982-8.
 Abstract
 
Pharmacokinetics and pharmacodynamics in HAART and antibiotic therapy.
Boffito M 
New Microbiol. 2007 Jul;30(3):346-9.
 Abstract
 
Successful HAART Is Associated with High B-Chemokine Levels in Chronic HIV Type
1-Infected Patients.
Brito A, Almeida A, Gonsalez CR. et al
AIDS Res Hum Retroviruses. 2007 Jul;23(7):906-12.
 Abstract
 
Continuous evidence of fast HIV disease progression related to class-wide resistance to
antiretroviral drugs: a 6 year follow-up analysis of a large observational database.
Mauro Z, Federica F, Patrizia L, et al
AIDS. 2007 Aug 20;21(13):1824-1826.
 Abstract
 
Impact of Ethnicity and HIV Type 1 Subtype on Response to First-Line Antiretroviral Therapy.
[Spain]
De Arellano ER, Benito JM, Soriano V, et al
 AIDS Res Hum Retroviruses. 2007 Jul;23(7):891-4.
 Abstract
 
A coronary heart disease risk model for predicting the effect of potent antiretroviral therapy
in HIV-1 infected men.
 May M, Sterne JA, Shipley M, et al
Int J Epidemiol. 2007 Jul 25;
 Abstract
 
The Antiretroviral Regimen Complexity Index: A Novel Method of Quantifying Regimen
Complexity.
Martin S, Wolters PL, Calabrese SK, et al 
J Acquir Immune Defic Syndr. 2007 Jun 21;
Abstract
 
Effects of potent antiretroviral therapy on free testosterone levels and fat-free mass in men in a
prospective, randomized trial: A5005s, a substudy of AIDS Clinical Trials Group Study 384.
Dubé MP, Parker RA, Mulligan K, et al
Clin Infect Dis. 2007 Jul 1;45(1):120-6.
 Abstract
 
Bone mineral density remains stable in HAART-treated HIV-infected men over 2 years.
Bolland MJ, Grey AB, Horne AM, et al 
Clin Endocrinol (Oxf). 2007 Jun 4;
Abstract
 
FULL TEXT PDF ARTICLE
Advances in HIV Therapy
 Jones J, Taylor B, Wilkin TJ, Hammer SM.
 Top HIV Med. 2007 Apr-May;15(2):48-82.
 Paper
 
Chronic HIV infection : Current therapeutic aspects.
Vogel M, Rockstroh JK
Internist (Berl). 2007 Apr 13;
 Abstract
 
FULL TEXT ARTICLE
 Ten years of highly active antiretroviral therapy for HIV infection.
 Chen LF, Hoy J, Lewin SR.
 Med J Aust. 2007 Feb 5;186(3):146-51.
 Paper
 
FULL TEXT ARTICLE
 Access to generic antiretrovirals: inequality, intellectual property law, and international
trade agreements.
 Castro A, Westerhaus M
 Cad Saude Publica. 2007 00;23:S85-S96.
Paper
 
Effect of Clinical Pharmacists on Utilization and Clinical Response to Antiretroviral Therapy.
Horberg MA, Hurley LB, Silverberg MJ , et al
J Acquir Immune Defic Syndr. 2007 Jan 11;
 Abstract
 
Discordant immunological and virological responses to antiretroviral therapy.
Schechter M, Tuboi SH.
Antimicrob Chemother. 2006 Jul 19;
 Abstract
 
Effect of Baseline- and Treatment-Related Factors on Immunologic Recovery After Initiation of
Antiretroviral Therapy in HIV-1-Positive Subjects: Results From ACTG 384.
Gandhi RT, Spritzler J, Chan E,et al  
J Acquir Immune Defic Syndr. 2006 Jun 26;
 Abstract
 
To Take or Not to Take: Decision-Making About Antiretroviral Treatment in People Living
with HIV/AIDS.
 Kremer H, Ironson G, Schneiderman N, Hautzinger M.
 AIDS Patient Care STDS. 2006 May;20(5):335-49.
 Abstract
 
Absence of seroreversion in 80 HAART-treated HIV-1 seropositive patients with at
least five-years undetectable plasma HIV-1 viral load.
Cornelissen M, Jurriaans S, Prins JM,
AIDS Res Ther. 2006 Feb 16;3(1):3
Abstract
 
Thymic Function in Severely Immunodeficient HIV Type 1-Infected Patients Receiving
Stable and Effective Antiretroviral Therapy.
Fernandez S, Nolan RC, Price P, et al  
AIDS Res Hum Retroviruses. 2006 Feb;22(2):163-70
 Abstract
 
Seroreversion in Subjects Receiving Antiretroviral Therapy during Acute/Early HIV Infection.
Hare CB, Pappalardo BL, Busch MP, Karlsson AC, et al 
Clin Infect Dis. 2006 Mar 1;42(5):700-8.
Abstract
 
Disease progression in patients with virological suppression in response to HAART
is associated with the degree of immunological response.
Moore DM, Hogg RS, Chan K, et al
 AIDS. 2006 Feb 14;20(3):371-7.
Abstract
 
Determinants of response to first HAART regimen in antiretroviral-naive patients with an
estimated time since HIV seroconversion.
Thiebaut R, Jacqmin-Gadda H, Walker S, et al 
HIV Med. 2006 Jan;7(1):1-9.
 Abstract
 
Amount of lymphatic tissue fibrosis in HIV infection predicts magnitude of HAART-associated
change in peripheral CD4 cell count.
Schacker TW, Reilly C, Beilman GJ, et al 
AIDS. 2005 Dec 2;19(18):2169-71
 Abstract
 
FULL TEXT ARTICLE
 HIV-infected individuals receiving effective antiviral therapy for extended periods of time
continually replenish their viral reservoir.
Chun TW, Nickle DC, Justement JS, et al
J Clin Invest. 2005 Nov 1;115(11):3250-3255.
Paper
 
AIDS events among individuals initiating HAART: do some patients experience a greater
benefit from HAART than others?
Sabine C;
AIDS. 2005 Nov 18;19(17):1995-2000.
 Abstract
 
Antiretroviral therapy: an update for the non-AIDS specialist.
Kalkut G.
Curr Opin Oncol. 2005 Sep;17(5):479-84
Abstract
 
Clinical outcome after 4 years follow-up of HIV-seropositive subjects with incomplete
virologic or immunologic response to HAART.
Nicastri E, Chiesi A, Angeletti C, Sarmati L, et al 
J Med Virol. 2005 Apr 15;76(2):153-16
 Abstract
 
Impact of highly active antiretroviral therapy on organ-specific manifestations of
HIV-1 infection.
Torre D, Speranza F, Martegani R.
HIV Med. 2005 Mar;6(2):66-78.
 Abstract
 
FULL TEXT ARTICLE
 Treatment exhaustion of highly active antiretroviral therapy (HAART) among
individuals infected with HIV in the United Kingdom: multicentre cohort
study
 Sabin CA,  Hill T, Lampe F, et al
BMJ  2005;330:695 (26 March)
 Paper
 
Why are Baseline HIV RNA Levels 100,000 Copies/mL or Greater Associated With
Mortality After the Initiation of Antiretroviral Therapy?
Wood E, Hogg RS, Yip B, Harrigan PR, Montaner JS.
J Acquir Immune Defic Syndr. 2005 Mar 1;38(3):289-295
 Abstract
 
Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART.
Nettles RE, Kieffer TL, Kwon P,
JAMA. 2005 Feb 16;293(7):817-29.
 Abstract
 
Late presenters in the era of highly active antiretroviral therapy: uptake of
and responses to antiretroviral therapy.
Sabin CA, Smith CJ, Gumley H, Murphy G, et al
AIDS. 2004 Nov 5;18(16):2145-51
 Abstract
 
Long-Term Follow-Up of HIV-Infected Individuals Who Have Significant Increases in
CD4+ Cell Counts during Antiretroviral Therapy.
Koletar SL, Williams PL, Wu J, et al 
Clin Infect Dis. 2004 Nov 15;39(10):1500-6.
 Abstract
 
FULL TEXT ARTICLE
 Limited Durability of Viral Control following Treated Acute HIV Infection
Kaufmann DE,  Lichterfeld M, Altfeld, M, et al
PLoS Medicine Vol 1, No 2
 Paper
 
HIV update: emerging clinical evidence and a review of recommendations for the
use of highly active antiretroviral therapy.
Kress KD.
Am J Health Syst Pharm. 2004 Oct 1;61 Suppl 3:S3-14
 Abstract
 
Pharmacologic Perspectives for Once-Daily Antiretroviral Therapy (CE) (November).
Anderson PL
Ann Pharmacother. 2004 Oct 12
Abstract
 
A significant proportion of HIV-infected patients admitted to hospital have
immunosuppression as a result of failure of highly active antiretroviral therapy.
Manavi K, McMillan A.
HIV Med. 2004 Sep;5(5):360-3.
 Abstract
 
Intensive Care in Patients With HIV Infection in the Era of Highly Active
Antiretroviral Therapy.
Narasimhan M, Posner AJ, DePalo VA,et al   
Chest. 2004 May;125(5):1800-4
 Abstract
 
Highly active antiretroviral therapy improves neurocognitive functioning.
 Robertson KR, Robertson WT, Ford S, et al 
J Acquir Immune Defic Syndr. 2004 Apr 15;36(1):562-6.
Abstract
 
FULL TEXT ARTICLE
Acute HIV revisited: new opportunities for treatment and prevention.
Pilcher CD, Eron JJ Jr, Galvin S, et al 
J Clinl Invest. 2004 Apr:113(7)037-45
 Paper
 
Quality assurance program for clinical measurement of antiretrovirals: AIDS
clinical trials group proficiency testing program for pediatric and adult
pharmacology laboratories.
Holland DT, DiFrancesco R, Stone J, et al    
Antimicrob Agents Chemother. 2004 Mar;48(3):824-31.
 Abstract
 
Antiretroviral Therapy in Patients with Hepatitis and HIV: Weighing Risks and Benefits.
Powderly WG.
Clin Infect Dis. 2004 Mar 1;38 Suppl 2:S109-13.
 Abstract
 
Determinants of long-term highly active antiretroviral treatment efficacy.
Manegold C, Thomas S, Jablonowski H, et al
HIV Med. 2004 Jan;5(1):40-9
 Abstract
 
Determinants of survival following HIV-1 seroconversion after the introduction of
HAART.
Porter K, Babiker A, Bhaskara